Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DKY709 Alone and in Combination With PDR001 in Advanced Solid Tumors
NCT03891953Phase 1Active, not recruiting
- Sponsor
- Novartis
- Start
- May 2019
- Primary completion
- Jun 2027
- Modality
- Molecular Glues
- Countries
- 6
01
Overview
Phase 1, open-label trial of DKY709 in non-small cell lung carcinoma (NSCLC), melanoma, nasopharyngeal carcinoma (NPC) and 2 more (2 arms), sponsored by Novartis. Primary endpoints: Safety of DKY709 single agent treatment or DKY709 in combination with PDR001 at 24 months, Incidence of Dose Limiting Toxicities at 1 month and 1 more. Started May 2019; status: active, not recruiting.
02
Drugs
DKY709
03
Conditions
non-small cell lung carcinoma (NSCLC)melanomanasopharyngeal carcinoma (NPC)colorectal cancer (CRC)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03891953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03891953.